Protein controlling gut's protective force field identified

Immune-system receptor encourages growth of bacterial shield during illness

Protein controlling gut's protective force field identified

140925-protein.pngDOI: 10.1016/j.chom.2014.08.017
In the absence of IL-22RA1, fucosylation does not occur in the gut, allowing opportunistic pathogens to infect the host.

Scientists have identified a protein in the human intestine that helps to protect against attack from opportunistic bacteria that strike when our defences are down. The protein receptor is activated during illness, producing a force field on the gut's surface made of a sugary substance that encourages the growth of protective bacteria.

Scientists deleted the IL-22RA1 gene that produces the receptor protein from the mouse genome. In the absence of this gene, which is associated with inflammatory bowel disease (IBD) in humans, the mice were found to be more susceptible to over-colonisation by harmful Enterococcus faecalis bacteria.

"The gut prevents over-colonisation by fuelling the growth of bacteria that will restore balance. We confirmed this by treating the mouse models with the intestinal coating produced in wild-type mice and found that many of them regained their former equilibrium."

Tu Anh Pham, first author from the Wellcome Trust Sanger Institute

Investigating the mechanism further in the lab, researchers found that the protective force field works by inducing fucosylation, where a sugar-like substance is produced that coats the surface of the epithelial cells of the intestine, creating a healthy microbiota in which a whole host of protective bacteria will thrive.

Using organoids, an emerging research tool that enables scientists to grow small intestinal tissue clusters using cells from the original tissue and stem cells, researchers were able to take a closer look at epithelial cells in which IL-22RA1 receptors were working correctly.

Researchers sequenced the organoid RNA, the molecules that regulate gene expression in these cells, to identify the series of pathways affected by the activation of the IL-22RA1 receptor. Many of the pathways identified have previously been linked to autoimmune diseases such as IBD. In addition, Fut2, the gene involved in the related process of fucolysation, has known links to Crohn's disease.

"In this research we've used the Sanger Institute's expertise in mouse genetics to look at the microbiota in the context of a whole system and in extraordinary detail on a cellular level using organoids. Both perspectives are indispensable in our work to understand the complex interplay between the host and the unique mixture of bacteria each one of us harbours."

Dr Trevor Lawley, Faculty member and senior author from the Sanger Institute

Now that researchers have a better understanding of the host's genetics, they can begin to identify the protective bacterial groups that proliferate when the IL-22RA1 receptor is activated. It is hoped that these bacterial species could be used therapeutically.

"We might, in the future, be able to harness what we know about this receptor and the bacteria it promotes to protect vulnerable patients. If we can replenish their microbiota and help them produce the correct environment in their gut, we will be able to give them the strength they need to battle infection."

Professor Arthur Kaser, Consultant Physician in the Department of Gastroenterology at Addenbrookes Hospital, Cambridge

Notes to Editors
Publications
  • Epithelial IL-22RA1-mediated fucosylation promotes intestinal colonization resistance to an opportunistic pathogen.

    Pham TA, Clare S, Goulding D, Arasteh JM, Stares MD et al.

    Cell host & microbe 2014;16;4;504-16

Funding

Please see the paper for details about funding.

Participating Centres

Please see the paper for a full list of participating centres.

Selected Websites
Contact the Press Office

Emily Mobley, Media Manager

Tel +44 (0)1223 496 851

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Dr Matthew Midgley, Media Officer

Tel +44 (0)1223 494 856

Wellcome Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7748 379849

Recent News

From childhood cancer to mapping human development: Pioneering scientist awarded 2019 Foulkes Foundation medal
Congratulations to Professor Muzlifah Haniffa, who has been recognised for her work on the immune system and childhood cancer
Dr Sam Behjati wins Liddy Shriver Early Career Research Award
Congratulations to Sanger Institute cancer researcher, Dr Sam Behjati, who has been recognised for his work in sarcoma cancer genomics
New malaria drug targets identified in liver stage of life cycle
Hope that new liver-stage drugs will help to counter the threat of antimicrobial resistance to current blood-stage medicines